LJ-2618

LJ-2618 is a novel third-generation selenonucleoside (4′-selenofuranosyl-2,6-dichloropurine) being investigated for its anti-tumor activity, particularly in paclitaxel-resistant and castration-resistant prostate cancer. Developed by researchers at Seoul National University, it functions by promoting the degradation and destabilization of the S-phase kinase-associated protein 2 (Skp2), an F-box protein often overexpressed in resistant cancer cells. This degradation leads to the stabilization of the cyclin-dependent kinase inhibitor p27, triggering G2/M cell cycle arrest and inhibiting tumor cell proliferation. Additionally, LJ-2618 has been shown to suppress the PI3K/Akt signaling pathway. Preclinical studies in xenograft mouse models have demonstrated its efficacy in inhibiting tumor growth at doses of 3 to 10 mg/kg.

Other names

4′-selenofuranosyl-2,6-dichloropurine